
    
      A phase 2, randomized, open-label, controlled study to evaluate the efficacy, safety, and
      immunogenicity of the vaccine administered three times (10 μg LEISH-F2 + 25 μg MPL-SE on Days
      0, 28 and 56) in the treatment of adults and adolescents with CL compared to treatment with
      standard chemotherapy (20 mg/kg/day sodium stibogluconate for 20 days). The proportion cured
      in each group will be determined using clinical criteria.
    
  